JNJ Surges on Dividends and Lung Cancer Breakthrough
Johnson & Johnson (JNJ) has been gaining traction among investors in recent weeks. The healthcare giant, known for its blockbuster drugs like Stelara and Darzalex, is a dividend aristocrat that continues to draw bullish views from Wall Street.
The company's stock price has surged 33% year-to-date, with analysts on TipRanks maintaining a Strong Buy rating and an average price target of $283.69, implying about 4% upside from current levels.
In addition to its pharmaceutical portfolio, Johnson & Johnson is expanding its presence in lung cancer care through diagnostics. The company has completed a pilot clinical study evaluating the Aquyre Biopsy Scanner, a class I device designed to assess the adequacy of small lung and lymph node biopsy samples in real-time during bronchoscopy.
The study found that the scanner performed well in routine bronchoscopic biopsies, reducing repeat procedures, shortening procedure times, and streamlining workflows. This technology could create a new recurring revenue stream for Johnson & Johnson, enhancing its long-term growth story beyond its established pharmaceutical portfolio.